SCHEMBL1964026

SCHEMBL1964026

COc1cnc2c(c1)cc(C(=O)CC1CCOCC1)n2S(=O)(=O)c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 3/20 0.37
NPC1 O15118 1/20 0.36
USP2 O75604 1/20 0.36
KMT2A Q03164 1/20 0.36
HDAC3 O15379 2/20 0.36
HDAC4 P56524 2/20 0.36
HDAC1 Q13547 2/20 0.36
HDAC7 Q8WUI4 2/20 0.36
HDAC2 Q92769 2/20 0.36
HDAC10 Q969S8 2/20 0.36
HDAC11 Q96DB2 2/20 0.36
HDAC8 Q9BY41 2/20 0.36
HDAC6 Q9UBN7 2/20 0.36
HDAC9 Q9UKV0 2/20 0.36
HDAC5 Q9UQL6 2/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.35
RIPK1 Q13546 1/20 0.35
POLB P06746 3/20 0.35
HSD17B10 Q99714 2/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1958748 0.92 FKBP1A (0.38) NPC1KMT2AHDAC3HDAC4HDAC1
SCHEMBL1960226 0.91 FKBP1A (0.38) PIK3CGKMT2AHDAC3HDAC4HDAC1
SCHEMBL1959015 0.86 RIPK1 (0.38) PTGDR2RIPK1POLBALDH1A1LMNA
SCHEMBL1963274 0.86 ALDH1A1 (0.40) USP2KMT2AHSD17B10ALDH1A1LMNA
SCHEMBL1963039 0.83 LMNA (0.43) PTGDR2RIPK1ALDH1A1LMNASMN1; SMN2
SCHEMBL1959821 0.82 NPC1 (0.36) PIK3CGNPC1USP2KMT2APTGDR2
SCHEMBL1960658 0.82 RORC (0.42)
SCHEMBL1962993 0.79 PDE5A (0.38) KMT2APTGDR2ALDH1A1LMNAPKM
SCHEMBL1958747 0.79 ALDH1A1 (0.38) KMT2AHSD17B10ALDH1A1LMNASMN1; SMN2
SCHEMBL1959207 0.79 AADAT (0.36) HSD17B10ALDH1A1LMNAHPGDHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2513103-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2012-10-24 EP disclosed
US-8222416-B2 Azaindole glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-07-17 US disclosed
WO-2011073117-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 WO disclosed
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 PIK3CG 1914/4885NPC1 3423/4885USP2 2799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.